Juq-063 !!hot!!

The JUQ-063 emerged from NovaTech’s collaboration with academic institutions and energy policymakers, ensuring alignment with international sustainability goals like the UN’s [2].

| Area | Rationale | |------|-----------| | | As a high‑affinity CB₁/CB₂ agonist, JUQ‑063 can help elucidate receptor signaling pathways, bias signaling, and the role of cannabinoid receptors in pain and inflammation. | | Structure‑activity relationship (SAR) studies | The indazole‑carboxamide scaffold offers a versatile platform for exploring modifications that affect potency, selectivity, and metabolic stability. | | Drug‑delivery investigations | Its lipophilicity makes it a candidate for formulation studies (e.g., nano‑emulsions, transdermal patches) aimed at targeted cannabinoid delivery. | | Toxicology testing | Provides a model compound for assessing the health risks associated with new synthetic cannabinoids entering the market. | JUQ-063

Tell me which of these (media, product, or technical code) you mean — or paste any extra context (an image, a link, or a sentence where you saw "JUQ-063") and I’ll provide a focused, detailed summary. | | Drug‑delivery investigations | Its lipophilicity makes

| Aspect | Findings | |--------|----------| | | LD₅₀ in mice ≈ 120 mg kg⁻¹ (oral). Signs of toxicity include sedation, ataxia, and, in some cases, seizures at supra‑therapeutic doses. | | Chronic exposure | Limited data; animal studies suggest tolerance development and modest receptor down‑regulation after repeated dosing. | | Potential adverse effects | ‑ Cardiovascular: tachycardia, hypertension ‑ Neurological: anxiety, paranoia, occasional psychosis‑like symptoms ‑ Gastrointestinal: nausea, vomiting ‑ Renal/hepatic: elevation of liver enzymes in some case reports | | Drug‑drug interactions | Because metabolism relies heavily on CYP3A4, concurrent use of strong inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin) can markedly alter plasma concentrations. | | Aspect | Findings | |--------|----------| | |

(A concise, literature‑synthesised write‑up, 2024‑2026 status)